NCT05248672View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

CT1812

Study Drug

Trial Locations (1)

32720

Accel Clinical Research, DeLand

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT05248672 - Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers | Biotech Hunter | Biotech Hunter